Lumos Pharma (NASDAQ:LUMO) Announces Quarterly Earnings Results

Lumos Pharma (NASDAQ:LUMOGet Free Report) released its quarterly earnings data on Tuesday. The company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.21) by ($0.08), Zacks reports. Lumos Pharma had a negative return on equity of 85.63% and a negative net margin of 1,659.39%. The business had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.51 million. During the same period in the previous year, the business posted ($0.89) earnings per share.

Lumos Pharma Stock Performance

Shares of NASDAQ LUMO traded down $0.31 during midday trading on Wednesday, reaching $2.24. 137,551 shares of the company traded hands, compared to its average volume of 26,970. Lumos Pharma has a 12 month low of $2.01 and a 12 month high of $4.55. The stock’s 50-day simple moving average is $2.81 and its 200-day simple moving average is $2.98. The firm has a market cap of $18.19 million, a PE ratio of -0.53 and a beta of 0.66.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and issued a $28.00 price target on shares of Lumos Pharma in a research report on Wednesday, March 20th.

Get Our Latest Research Report on LUMO

About Lumos Pharma

(Get Free Report)

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.

Recommended Stories

Earnings History for Lumos Pharma (NASDAQ:LUMO)

Receive News & Ratings for Lumos Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lumos Pharma and related companies with's FREE daily email newsletter.